Adamant Biomedical Investments’s Bristol-Myers Squibb BMY Stock Holding History

Adamant Biomedical Investments’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$3.54M	Buy	60,000 +10,000	+20%	+$564K	0.85%	44
2014 Q3	$2.56M	Buy	+50,000	New	+$2.5M	0.64%	51

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Adamant Biomedical Investments's BMY Position: Q4 2014 in Review

Adamant Biomedical Investments increased its Bristol-Myers Squibb (BMY) stake by 20% in Q4 2014, buying an estimated $564K and bringing the position to 60,000 shares worth $3.54M. The position accounts for 0.85% of the portfolio, ranked #44.

Adamant Biomedical Investments first reported a position in BMY in Q3 2014 and has held it in 2 quarters since. 1,411 funds tracked by Wall St. Rank hold BMY as of Q4 2014.

Adamant Biomedical Investments held 60,000 shares of Bristol-Myers Squibb worth $3.54M as of Q4 2014.
Adamant Biomedical Investments bought 10,000 Bristol-Myers Squibb shares in Q4 2014, an estimated $564K.
Bristol-Myers Squibb made up 0.85% of Adamant Biomedical Investments's portfolio in Q4 2014, its #44 holding.
Adamant Biomedical Investments first reported a position in Bristol-Myers Squibb in Q3 2014 and has held it in 2 quarters since.
1,411 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.